Cogent Biosciences, Inc. (COGT)
34.44
-0.12
(-0.36%)
USD |
NASDAQ |
Sep 03, 10:42
Cogent Biosciences Research and Development Expense (TTM) : 285.88M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 285.88M |
| March 31, 2026 | 277.48M |
| December 31, 2025 | 265.16M |
| September 30, 2025 | 251.67M |
| June 30, 2025 | 246.34M |
| March 31, 2025 | 238.51M |
| December 31, 2024 | 228.26M |
| September 30, 2024 | 215.30M |
| June 30, 2024 | 202.05M |
| March 31, 2024 | 186.49M |
| December 31, 2023 | 170.17M |
| September 30, 2023 | 158.05M |
| June 30, 2023 | 138.46M |
| March 31, 2023 | 130.18M |
| December 31, 2022 | 120.27M |
| September 30, 2022 | 104.91M |
| June 30, 2022 | 89.98M |
| Date | Value |
|---|---|
| March 31, 2022 | 72.97M |
| December 31, 2021 | 55.77M |
| September 30, 2021 | 41.43M |
| June 30, 2021 | 31.68M |
| March 31, 2021 | 24.44M |
| December 31, 2020 | 25.74M |
| September 30, 2020 | 29.98M |
| June 30, 2020 | 35.32M |
| March 31, 2020 | 40.80M |
| December 31, 2019 | 43.71M |
| September 30, 2019 | 44.12M |
| June 30, 2019 | 44.04M |
| March 31, 2019 | 42.55M |
| December 31, 2018 | 38.28M |
| September 30, 2018 | 35.08M |
| June 30, 2018 | 33.01M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Apogee Therapeutics, Inc. | 240.59M |
| Erasca, Inc. | 108.88M |
| Moderna, Inc. | 2.635B |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |